| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced new preclinical data showing the potential of SRK-439 topreserve lean mass and improve metabolic health as part of healthy weight loss. These data showed that SRK-439 maintained lean mass and improved fat mass loss when used in combination with a GLP-1 receptor agonist (GLP-1 RA; in separate experiments with semaglutide and liraglutide) in diet-induced obesity (DIO) mice. SRK-439 treatment also led to incremental lowering of fasting glucose beyond the levels seen with semaglutide alone. Detailed results were presented by Melissa Fulham, PhD, of Scholar Rock, at the Keystone Symposia'sObesity: Causes and Consequences meeting in Vancouver, BC, Canada on February 5.
"These preclinical data showing that SRK-439 preserves lean mass and improves fat mass loss provide compelling scientific rationale to study SRK-439 in combination with GLP-1 RA therapies for healthy weight loss management," said Jay Backstrom, M.D., MPH, President and CEO of Scholar Rock. "We believe that preserving lean muscle mass through our highly selective approach to myostatin inhibition in combination with GLP-1 RA therapy has the potential to transform the management of weight loss. We look forward to initiating our proof-of-concept study with apitegromab in combination with GLP-1 RA therapy in obesity as we also continue to advance SRK-439 to clinic."
In January, Scholar Rock announced that the U.S. Food and Drug Administration cleared the company's Investigational New Drug (IND) application for its Phase 2 proof-of-concept trial of apitegromab to treat obesity in patients taking a GLP-1 RA. Trial initiation is on track for mid-2024, and data from the apitegromab Phase 2 trial are expected in mid-2025. In parallel, Scholar Rock is developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity.
Selectivity and affinity: SRK-439 works by selectively binding to the pro- and latent forms of myostatin, as confirmed through in vitro ELISA testing that shows SRK-439 does not bind to closely related TGFβ family members GDF11 and Activin A, both of which, if inhibited, have potentially detrimental effects outside of the muscle. The studies confirmed that SRK-439 binds to latent myostatin with 0.579 nM affinity. This selectivity and affinity, along with favorable developability characteristics and durable pharmacokinetics suggests that SRK-439 could be suitable for dosing in a subcutaneous formulation and in a low dose volume in a population of adults with obesity.
Changes in body weight, lean mass, and fat mass: Quantitative nuclear magnetic resonance (qNMR) was used to analyze body composition in DIO mice in two separate experiments. In the first, mice received either liraglutide, 0.06 mg/kg daily, or liraglutide, at the same dose, plus SRK-439 in either a 0.3, 1.0, or 3.0 mg/kg weekly dose. In the second experiment, DIO mice received either semaglutide, 0.04 mg/kg daily or semaglutide, at the same dose, plus SRK-439 in either a 0.1, 0.3, 1.0, or 3.0 mg/kg weekly dose. Total body weight, lean mass, and fat mass were assessed. As expected, both liraglutide and semaglutide reduced body weight in DIO mice compared to baseline. SRK-439 diminished the GLP-1 RA-driven lean mass loss in combination with semaglutide (–7.55% to –1.43% change from baseline in lean mass) and with liraglutide (1.98% to 5.55% from baseline). These results were dose-dependent: lean mass was preserved more as the dose of SRK-439 increased. SRK-439 also improved fat mass loss (–36.60% to –46.32% from baseline with semaglutide; –17.31% to –19.04% from baseline with liraglutide).
Results below are shown for the 3 mg/kg dose group of SRK-439 as compared to the IgG control group in each experiment (IgG + semaglutide or IgG + liraglutide), with the full results available on the poster in the Posters and Presentations section of the Scholar Rock website.
| Experiment 1: Liraglutide | Experiment 2: Semaglutide | |||
| IgG Control | SRK-439 (3mg/kg) | IgG Control | SRK-439 (3mg/kg) | |
| Change in Lean Mass from Baseline | –4.5% (n=8; p<0.0001) | 5.6% (n=8; p<0.0001) | –11.3% (n=8; P<0.0001) | –1.4% (n=8; p<0.0001) |
| Change in Fat Mass from Baseline | 0.4% (n=8; p<0.001) | –18.6% (n=8; ns) | –36.6% (n=8; ns) | –37.99 (n=8; ns) |
Changes in fasting glucose Fasting glucose was measured on Day 18 of the study in DIO mice that had received treatment with either semaglutide or semaglutide in combination with SRK-439. Mean fasting glucose levels were lower in mice receiving SRK-439, with results for 0.3, 1.0, and 3.0 mg/kg reaching significance compared to semaglutide + IgG control alone (103.0 – 107.8 mg/dL; p<0.05).
For conference information, visit https://www.keystonesymposia.org/.
The poster is available in the Publications & Posters section of Scholar Rock's website.
About SRK-439
SRK-439 is a novel, preclinical, investigational myostatin inhibitor that has high in vitro affinity for pro- and latent myostatin and maintains myostatin specificity (i.e., no GDF11 or Activin-A binding), and is initially being developed for the treatment of obesity. Based on preclinical data, SRK-439 has the potential to support healthier weight management by preserving lean mass. The efficacy and safety of SRK-439 have not been established and SRK-439 has not been approved for any use by the FDA or any other regulatory agency.
Posted In: SRRK
